What is the Bolt Biotherapeutics Inc. stock price forecast?

Bolt Biotherapeutics Inc. is currently trading at $4.56. View real-time AI analysis on Alpha Lenz.

What is Bolt Biotherapeutics Inc. insider trading activity?

View the latest insider trading data for Bolt Biotherapeutics Inc. on Alpha Lenz.

What is Bolt Biotherapeutics Inc.'s P/E ratio?

Bolt Biotherapeutics Inc.'s P/E ratio is -0.3.

Bolt Biotherapeutics Inc.

NASDAQ · BOLT

$4.56-0.21(-4.40%)Pre-market

Ask about Bolt Biotherapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Bolt Biotherapeutics Inc. trades at a P/E of -0.3 (undervalued) with modest ROE of -79.7%. 3Y revenue CAGR of 10.3% highlights clear growth momentum.”

Ask for details →

Company Overview

Bolt Biotherapeutics Inc. is a clinical-stage biotechnology company that focuses on developing advanced immunotherapies for the treatment of cancer. The company's primary goal is to harness the body's immune system to specifically target and destroy tumor cells, leveraging a proprietary platform known as Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate). This innovative approach aims to engage and activate the innate immune system, potentially offering novel therapeutic options for patients with difficult-to-treat cancers. Working primarily within the health sciences and pharmaceutical sectors, Bolt Biotherapeutics' research and developments are significant for the advancement of targeted cancer therapies. Founded in 2015 and headquartered in Redwood City, California, the company's efforts contribute to the growing landscape of immuno-oncology, a critical area in the pursuit of durable cancer treatments.

CEOMr. William P. Quinn

Websitehttps://www.boltbio.com

SectorHealthcare

IndustryBiotechnology

Employees52

Company Statistics

FY 2025

Profile

$8.53MMarket Cap

$7.70MRevenue

0.00Shares Out

52Employees

Margins

N/AGross

-414.06%EBITDA

-450.07%Operating

-433.74%Pre-Tax

-433.74%Net

Valuation

-0.26P/E

0.32P/B

1.11EV/Sales

-0.62EV/EBITDA

-0.21P/FCF

Growth (CAGR)

10.33%Rev 3Yr

101.61%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-42.69%ROA

-79.75%ROE

-44.29%ROIC

Financial Health

$11.70MCash & Cash Equivalents

$18.54MNet Debt

114.10%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Bolt Biotherapeutics Inc. trades at a P/E of -0.3 (undervalued) with modest ROE of -79.7%. 3Y revenue CAGR of 10.3% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Bolt Biotherapeutics Inc. (ticker: BOLT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 52 employees. Market cap is $9M.

The current price is $4.56 with a P/E ratio of -0.26x and P/B of 0.32x.

ROE is -79.75% and operating margin is -450.07%. Annual revenue is $8M.